CYP51A1 and Chagas disease: Despite these disadvantages, a high throughput screening (HTS) assay based on the shift of the heme iron Soret band in response to small molecule binding has been successfully applied to CYP51's counterpart in Mycobacterium tuberculosis[22], ultimately resulting in identification of a potent T. cruzi inhibitor [14], [23] whose drug-like properties for Chagas Disease are currently being optimized.